319
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

The effect of different rituximab-containing chemotherapy strategies on hepatitis C viremia

, , , &
Pages 1487-1490 | Received 12 Aug 2015, Accepted 19 Sep 2015, Published online: 16 Nov 2015
 

Acknowledgements

Presented in part at the 56th Annual Meeting of the American Society of Hematology, December 6–9, 2014, San Francisco, CA.

Potential conflict of interest

Harrys A. Torres is a consultant for Janssen Pharmaceuticals, Gilead Sciences, Merck & Co., Vertex Pharmaceuticals, Novartis, Genentech, Astellas, Pfizer, and Theravance and received research grants from Gilead Sciences, Merck & Co., and Vertex Pharmaceuticals. All other authors had no potential conflicts of interest to disclose. Disclosure forms provided by the authors are available with the full text of this article at http://dx.doi.org/10.3109/10428194.2015.1099649

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.